 |
| 18-Apr-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$48 → $45 |
|
| 16-Jan-13 | Reiterated |
Deutsche Bank |
Hold |
$34 → $36 |
|
| 09-Nov-12 | Initiated |
Mizuho |
Buy |
$45 |
|
| 26-Apr-12 | Initiated |
Auriga |
Hold |
$36 |
|
| 18-Apr-12 | Reiterated |
Cantor Fitzgerald |
Buy |
$41 → $45 |
|
| 09-Dec-11 | Initiated |
Barclays Capital |
Equal Weight |
$30 |
|
| 25-Oct-11 | Downgrade |
Argus |
Buy → Hold |
|
|
| 19-Oct-11 | Reiterated |
UBS |
Neutral |
$34 → $32 |
|
| 15-Sep-11 | Reiterated |
UBS |
Neutral |
$40 → $34 |
|
| 22-Jun-11 | Upgrade |
Argus |
Hold → Buy |
$46 |
|
| 20-Oct-10 | Reiterated |
UBS |
Neutral |
$34.32 |
|
| 14-Sep-10 | Reiterated |
UBS |
Neutral |
$29 → $32 |
|
| 14-Sep-10 | Reiterated |
Deutsche Bank |
Hold |
$29 → $33 |
|
| 09-Jun-10 | Initiated |
Caris & Company |
Buy |
$36 |
|
| 21-Apr-10 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 08-Apr-10 | Downgrade |
Piper Jaffray |
Neutral → Underweight |
$27 → $26 |
|
| 05-Jan-10 | Reiterated |
Wedbush Morgan |
Neutral |
$32 → $35 |
|
| 18-Dec-09 | Initiated |
Soleil |
Buy |
$38 |
|
| 17-Dec-09 | Initiated |
Oppenheimer |
Outperform |
$40 |
|
| 02-Oct-09 | Initiated |
Jefferies & Co |
Buy |
$36 |
|
|
|
| 22-May-13 12:15AM | Google Joins Apple Avoiding Taxes With Stateless Income at Bloomberg |
| 21-May-13 01:41PM | Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide at Seeking Alpha |
| 09:27AM | Is There a Pill For That? Forest Labs Iffy Pipeline YCharts |
| 20-May-13 05:01PM | Teva Bets on Reformulating Old Drugs as Investors Say Show Me at Bloomberg |
| 01:56PM | July Options Now Available For Forest Laboratories (FRX) at TheStreet |
| 17-May-13 08:08AM | Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference Business Wire |
| 16-May-13 01:23PM | Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund, Interviews with The Wall Street Transcript: Investing in Health Care Innovation Wall Street Transcript |
| 08:00AM | Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting Business Wire |
| 14-May-13 11:59AM | Forest Reaches New 52-Week High (FRX) at TheStreet |
| 11:10AM | Forest-Trevena Ink Deal Zacks |
| 08:00AM | Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013 Business Wire |
| 13-May-13 12:01AM | Europe Eases Corporate Tax Dodge as Worker Burdens Rise at Bloomberg |
| 10-May-13 10:12AM | Analyst Moves: MU, FRX, AES, CVC at Forbes |
| 08:45AM | Analysts' Actions: MU BSX CVC FRX at TheStreet |
| 09-May-13 06:02AM | InPlay: Forest Labs and Trevena announce a collaborative agreement for development of TRV027 for the treatment of acute heart failure; co leads Trevena's $60 mln Series C funding round with a $30 mln investment Briefing.com |
| 06:00AM | Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure PR Newswire |
| 06:00AM | Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure Business Wire |
| 07-May-13 03:30PM | Positive Data on Forest Combo Drug Zacks |
| 06-May-13 01:47PM | Analyst downgrades Ironwood Pharma on expenses AP |
| 05-May-13 02:30PM | Take a Deep Breath Before This Big FDA Decision at Motley Fool |
| 03-May-13 12:33PM | Icahn Enterprises 1Q net income surges AP |
| 08:15AM | Mylan Reports in line Earnings Zacks |
| 02-May-13 11:08AM | Alternative Dosage Forms Create Barriers Against Competition in Generics: A Wall Street Transcript Interview with David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co. Wall Street Transcript |
| 08:34AM | 3 Healthcare Stock Stories For Midweek Wellness at Wall St. Cheat Sheet |
| 04:13AM | Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD CNW Group |
| 03:47AM | Almirall, Forest to seek approval for inhaler drug in US, Europe at Reuters |
| 01-May-13 02:19PM | InPlay: Forest Labs and Almirall announce positive results for the Second Phase III study for aclidinium and formoterol combination in COPD Briefing.com |
| 02:17PM | Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD Business Wire |
| 27-Apr-13 07:30AM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 26-Apr-13 11:48AM | Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street Transcript Wall Street Transcript |
| 25-Apr-13 11:46AM | Synergy On Sale: Why This Opportunity Shouldn't Be Missed at Seeking Alpha |
| 24-Apr-13 03:30PM | Loss Widens at Ironwood Zacks |
| 23-Apr-13 03:40PM | Forest Laboratories Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 03:25PM | Ironwood Pharma skids following 1st-quarter report AP |
| 02:30PM | Forest Labs' Earnings Decline Zacks |
| 10:27AM | Forest Labs fiscal 4Q profit plunges AP |
| 10:25AM | Forest Laboratories Earnings: Heres Why Shares are Up Now at Wall St. Cheat Sheet |
| 08:18AM | Ironwood's Constipation Drug Sales Disappoint at TheStreet |
| 08:13AM | Early Movers: DD, TRV, UTX & More at CNBC |
| 07:14AM | InPlay: Forest Labs beats by $0.09, beats on revs; guides FY14 EPS below consensus Briefing.com |
| 07:07AM | Q4 2013 Forest Laboratories, Inc. Earnings Release - Before Market Open CCBN |
| 07:00AM | Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization Business Wire |
| 02:51AM | FOREST LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online |
| 22-Apr-13 11:30AM | Forest Labs Likely to Miss 4Q Earnings Zacks |
| 20-Apr-13 12:30AM | A Make-or-Break Week Ahead for the Stock Market at CNBC |
| 18-Apr-13 03:30PM | Positive Data on Forest Candidate Zacks |
| 01:52PM | EBay Gets Booed and 4 More Analyst Downgrades to Know Now at Wall St. Cheat Sheet |
| 12:25PM | Analysts: J.C. Penney Should be Bought On Weakness and 2 Other Notes To Look Into at Wall St. Cheat Sheet |
| 17-Apr-13 10:35AM | Amarantus LymPro Could Be A Game-Changer For Alzheimer's Diagnosis at Seeking Alpha |
| 16-Apr-13 05:01PM | Today's Drugs Industry Featured Laggard: Forest Laboratories Inc. (FRX) at TheStreet |
| 04:13PM | Notable Two Hundred Day Moving Average Cross - FRX at TheStreet |
| 09:38AM | Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD CNW Group |
| 08:11AM | Early Movers: KO, GS, JNJ & More at CNBC |
| 02:58AM | Almirall, Forest report positive results in inhaler trial at Reuters |
| 02:32AM | InPlay: Forest Labs and Almirall report Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD Briefing.com |
| 02:30AM | Almirall and Forest Laboratories Announce Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD Business Wire |
| 15-Apr-13 01:03PM | 5 Stocks Pushing The Drugs Industry Downward at TheStreet |
| 14-Apr-13 01:43PM | GlaxoSmithKline: Not Making The Right Moves at Seeking Alpha |
| 12-Apr-13 09:35AM | Is Acadia A Buy After Jumping Over 50%? at Seeking Alpha |
| 08:42AM | Home Depot Opposes Plastic Settlement and 2 Stocks at 52-Week Highs at Wall St. Cheat Sheet |
| 10-Apr-13 03:00PM | Forest Laboratories Becomes #183 Most Shorted S&P 500 Component, Replacing Allergan at TheStreet |
| 09-Apr-13 06:13PM | Synergy Pharma rises as analyst raises sales view AP |
| 02:30PM | Synergy Pharma rises as analyst raises sales view AP |
| 02-Apr-13 02:29PM | UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers at Reuters |
| 10:07AM | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Fourth Quarter Earnings Business Wire |
| 08:31AM | Forest Labs initiated with a Neutral at Susquehanna theflyonthewall.com |
| 27-Mar-13 12:02PM | Ziopharm Considers Options After Drug Failure at TheStreet |
| 11:10AM | Ziopharm Considers Options After Drug Failure at TheStreet |
| 26-Mar-13 11:32AM | UPDATE 2-Lundbeck hopes Alzheimer's deal will be US blockbuster at Reuters |
| 10:00AM | Gains In This Biotech Could Soon Become Infectious to Investors at Motley Fool |
| 23-Mar-13 04:47AM | [$$] A Rewarding Development at Barrons.com |
| 18-Mar-13 12:00PM | Identifying Pipelines in Medical Devices: An Expert Equity Analyst Shares His Take on R&D in the Healthcare Industry and Shares Some of his Top Stock Picks Wall Street Transcript |
| 15-Mar-13 04:31PM | Ironwood shares rally after raised to 'Outperform' AP |
| 01:36PM | Ironwood shares rally after raised to 'Outperform' AP |
| 13-Mar-13 01:10PM | Forest Laboratories Inc. Presents at Barclays Global Healthcare Conference, Mar-13-2013 10:15 AM at Seeking Alpha |
| 03-Mar-13 09:57AM | Which of These 5 Pharma Stocks have the Strongest Earnings Trends? at Wall St. Cheat Sheet |
| 27-Feb-13 10:00PM | Forest Laboratories Inc. Presents at Citi 2013 Global Healthcare Conference, Feb-27-2013 10:20 AM at Seeking Alpha |
| 21-Feb-13 10:40AM | Carl Icahn's Latest Top 5: How Should Investors Play It? at Seeking Alpha |
| 19-Feb-13 01:23AM | Why Forest Laboratories May Be About to Take Off at Motley Fool |
| 13-Feb-13 04:51PM | Lundbeck Could Cheer Up Patient Investors at Seeking Alpha |
| 01:04PM | FOREST LABORATORIES INC Financials EDGAR Online Financials |
| 12-Feb-13 04:26PM | Shire to Forest on Deal List for AstraZeneca: Real M&A at Bloomberg |
| 02:34PM | Five Super Ideas in the Healthcare Sector at Motley Fool |
| 02:26PM | Shire to Forest on Deal List for AstraZeneca: Real M&A at Bloomberg |
| 10:15AM | Shire to Forest on Deal List for AstraZeneca: Real M&A at Bloomberg |
| 11-Feb-13 07:53PM | Shire to Forest on Deal List for AstraZeneca: Real M&A at Bloomberg |
| 08-Feb-13 03:46PM | High-Quality Glaxo Could Still Have Something Left at Seeking Alpha |
| 10:14AM | Post-Tysabri, Will Elan Waste The Windfall? at Seeking Alpha |
| 07-Feb-13 05:19PM | FOREST LABORATORIES INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 06-Feb-13 11:28AM | Forest Wins Denial of Drug Lawsuit Class Certification at Bloomberg |
| 11:28AM | Forest Wins Denial of Drug Lawesuit Class Certification at Bloomberg |
| 05-Feb-13 10:15AM | From Perspectives to Struggles, Alzheimer's Family Caregivers Find Strength in Sharing PR Newswire |
| 06:46AM | Forest Laboratories Goes Off Lexapro- What Happens Next? at Seeking Alpha |
| 31-Jan-13 09:27AM | New Stock Coverage: Forest Labs Looks Like a Money Tree at Minyanville |
| 30-Jan-13 03:33AM | Positive Top Line Data For Synergy: A Ripe Time For Acquisition at Seeking Alpha |
| 29-Jan-13 04:48PM | A Different Pharma Story Altogether at Motley Fool |
| 04:42PM | Boehringer Lung Drug Wins U.S. FDA Advisory Panel Backing at Bloomberg |
| 25-Jan-13 09:02AM | Boehringers Lung Drugs Benefits Questioned at Bloomberg |
| 08:41AM | Spring For This Forest at Motley Fool |
| 08:22AM | Boehringers Lung Drugs Benefits Questioned at Bloomberg |
|
|
| Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic for the treatment of hypertension; Savella for the management of fibromyalgia; Teflaro for the treatment of adults with skin and skin structure infections, and community-acquired bacterial pneumonia; Daliresp to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD; and Viibryd for the treatment of adults with major depressive disorder (MDD). The company has products under new drug application review by Food and Drug Administration comprising Aclidinium for the maintenance treatment of COPD; and Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. It also develops ceftaroline/avibactam combination, which is under Phase III clinical trials for complicated intra-abdominal infections, as well as has completed Phase II clinical trials for complicated urinary tract infections; and Cariprazine that is in Phase III clinical trials for the treatment of acute exacerbation of schizophrenia and acute mania associated with bipolar disorder. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; GRT 6005 that is under Phase II clinical trials for nociceptive and neuropathic pain; TTP399, which is under Phase II clinical trials for the treatment of Type II diabetes; and RGH-618 that is under Phase I clinical trials for the treatment of anxiety, depression, and other central nervous system conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. The company was founded in 1956 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Basgoz Nesli | Director | Mar 07 | Option Exercise | 27.40 | 9,621 | 263,633 | 18,695 | Mar 11 02:59 PM | | Basgoz Nesli | Director | Mar 07 | Sale | 37.46 | 12,200 | 456,954 | 6,495 | Mar 11 02:59 PM | | OLANOFF LAWRENCE S | Director | Mar 04 | Sale | 36.77 | 543 | 19,968 | 90,697 | Mar 04 03:20 PM | | Meury William | SVP - Marketing | Feb 06 | Option Exercise | 26.65 | 26,350 | 702,243 | 108,266 | Feb 08 09:30 AM | | Meury William | SVP - Marketing | Feb 06 | Sale | 35.73 | 26,350 | 941,603 | 81,916 | Feb 08 09:30 AM | | Weinstein Herschel S | SVP General Counsel | Jan 18 | Sale | 36.57 | 7,000 | 255,961 | 87,885 | Jan 23 10:09 AM | | Francis Perier I Jr | EVP Finance & Admin. & CFO | Dec 10 | Sale | 36.52 | 15,942 | 582,125 | 94,665 | Dec 12 11:26 AM | | Taglietti Marco | Sr.VP-R&D & Chief Medical Off. | Sep 06 | Sale | 35.51 | 13,000 | 461,631 | 107,568 | Sep 10 01:42 PM | | ICAHN CARL C | 10% Owner | Sep 05 | Buy | 34.65 | 561 | 19,439 | 30,286,349 | Sep 07 05:39 PM | | OLANOFF LAWRENCE S | Director | Sep 05 | Sale | 34.90 | 561 | 19,581 | 91,240 | Sep 06 01:12 PM | | ICAHN CARL C | 10% Owner | Sep 04 | Buy | 34.65 | 16,859 | 584,164 | 30,285,788 | Sep 04 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 31 | Buy | 34.65 | 6,274 | 217,394 | 30,268,929 | Sep 04 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 30 | Buy | 34.63 | 63,715 | 2,206,450 | 30,262,655 | Sep 04 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 29 | Buy | 34.65 | 130,728 | 4,529,725 | 30,198,940 | Aug 29 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 28 | Buy | 34.64 | 4,052 | 140,361 | 30,068,212 | Aug 29 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 27 | Buy | 34.65 | 196,626 | 6,813,091 | 30,064,160 | Aug 29 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 24 | Buy | 34.64 | 152,442 | 5,280,591 | 29,867,534 | Aug 24 05:14 PM | | ICAHN CARL C | 10% Owner | Aug 23 | Buy | 34.59 | 562,777 | 19,466,456 | 29,715,092 | Aug 24 05:14 PM | | ICAHN CARL C | 10% Owner | Aug 22 | Buy | 34.53 | 628,618 | 21,706,180 | 29,152,315 | Aug 24 05:14 PM | | ICAHN CARL C | 10% Owner | Aug 21 | Buy | 34.35 | 732,460 | 25,160,001 | 28,523,697 | Aug 21 05:26 PM | | ICAHN CARL C | 10% Owner | Aug 20 | Buy | 34.14 | 371,551 | 12,684,751 | 27,791,237 | Aug 21 05:26 PM | | ICAHN CARL C | 10% Owner | Aug 17 | Buy | 34.05 | 858,000 | 29,212,900 | 27,419,686 | Aug 21 05:26 PM | | Lynch Jerome | SVP-Sales | Aug 03 | Sale | 32.77 | 1,500 | 49,149 | 69,300 | Dec 07 03:55 PM |
|
|
|
|
|
|
